Tissue tropisms, infection kinetics, histologic lesions, and antibody response of the MR766 strain of Zika virus in a murine model.

Publisher: BioMed Central Country of Publication: England NLM ID: 101231645 Publication Model: Electronic Cited Medium: Internet ISSN: 1743-422X (Electronic) Linking ISSN: 1743422X NLM ISO Abbreviation: Virol J Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2004-

Disease Models, Animal* ; Viral Tropism*; Animal Structures/*pathology ; Antibodies, Viral/*blood ; Zika Virus/*physiology ; Zika Virus Infection/*pathology ; Zika Virus Infection/*virology; Animal Structures/virology ; Animals ; Antibody Formation ; Disease Outbreaks ; Histocytochemistry ; Humans ; Immunohistochemistry ; Mice ; Microscopy ; Time Factors ; Zika Virus/immunology ; Zika Virus Infection/epidemiology ; Zika Virus Infection/immunology

Background: The appearance of severe Zika virus (ZIKV) disease in the most recent outbreak has prompted researchers to respond through the development of tools to quickly characterize transmission and pathology. We describe here another such tool, a mouse model of ZIKV infection and pathogenesis using the MR766 strain of virus that adds to the growing body of knowledge regarding ZIKV kinetics in small animal models.
Methods: We infected mice with the MR766 strain of ZIKV to determine infection kinetics via serum viremia. We further evaluated infection-induced lesions via histopathology and visualized viral antigen via immunohistochemical labeling. We also investigated the antibody response of recovered animals to both the MR766 and a strain from the current outbreak (PRVABC59).
Results: We demonstrate that the IRF3/7 DKO mouse is a susceptible, mostly non-lethal model well suited for the study of infection kinetics, pathological progression, and antibody response. Infected mice presented lesions in tissues that have been associated with ZIKV infection in the human population, such as the eyes, male gonads, and central nervous system. In addition, we demonstrate that infection with the MR766 strain produces cross-neutralizing antibodies to the PRVABC59 strain of the Asian lineage.
Conclusions: This model provides an additional tool for future studies into the transmission routes of ZIKV, as well as for the development of antivirals and other therapeutics, and should be included in the growing list of available tools for investigations of ZIKV infection and pathogenesis.

JAMA Ophthalmol. 2016 Nov 1;134(11):1330-1332. (PMID: 27632055)
Cell Host Microbe. 2016 May 11;19(5):720-30. (PMID: 27066744)
Emerg Infect Dis. 2015 Jan;21(1):84-6. (PMID: 25530324)
Virol J. 2013 Oct 22;10:311. (PMID: 24148652)
Euro Surveill. 2016 Apr 21;21(16):. (PMID: 27123558)
Lancet. 2016 Jun 18;387(10037):2502. (PMID: 27287830)
J Infect Dis. 2016 Nov 1;214(9):1357-1360. (PMID: 27521359)
PLoS One. 2014 Oct 13;9(10):e109442. (PMID: 25310102)
Euro Surveill. 2014 Jan 30;19(4):. (PMID: 24507466)
East Afr Med J. 2010 Jun;87(6):262-8. (PMID: 23057269)
Cell Rep. 2016 Aug 9;16(6):1485-1491. (PMID: 27481466)
PLoS Negl Trop Dis. 2016 May 05;10(5):e0004658. (PMID: 27149521)
Nat Commun. 2016 Jun 28;7:12204. (PMID: 27352279)
Arq Bras Oftalmol. 2016 Feb;79(1):1-3. (PMID: 26840156)
Lancet. 2016 Apr 2;387(10026):1481. (PMID: 26946926)
Pathog Dis. 2015 Dec;73(9):ftv101. (PMID: 26519448)
N Engl J Med. 2020 Aug 6;383(6):e44. (PMID: 27305043)
Virol J. 2014 Mar 12;11:48. (PMID: 24620925)
N Engl J Med. 2016 Jul 28;375(4):394-6. (PMID: 27332784)
BMJ. 2016 Feb 10;352:i855. (PMID: 26864344)
Nature. 2016 Dec 15;540(7633):438-442. (PMID: 27798603)
Cell. 2016 Dec 1;167(6):1511-1524.e10. (PMID: 27884405)
J Hyg (Lond). 1979 Oct;83(2):213-9. (PMID: 489960)
Lancet Infect Dis. 2016 Oct;16(10):1107. (PMID: 27676342)
Emerg Infect Dis. 2011 May;17(5):880-2. (PMID: 21529401)
Clin Microbiol Rev. 2016 Jul;29(3):659-94. (PMID: 27281741)
Lancet. 2016 Jul 23;388(10042):337-338. (PMID: 27477155)
Brain. 2016 Aug;139(Pt 8):2122-30. (PMID: 27357348)
Lancet. 2016 Aug 27;388(10047):891-7. (PMID: 27372398)
Lancet. 2016 May 21;387(10033):2125-2132. (PMID: 26993883)
Am J Trop Med Hyg. 2016 Jun 1;94(6):1362-1369. (PMID: 27022155)
Cell Res. 2016 Jun;26(6):645-54. (PMID: 27174054)
Viral Immunol. 2008 Jun;21(2):123-32. (PMID: 18476771)
Lancet. 2017 Jan 7;389(10064):125-126. (PMID: 27939402)
N Engl J Med. 2016 Apr 21;374(16):1595-6. (PMID: 26958738)
Trans R Soc Trop Med Hyg. 1989 Nov-Dec;83(6):851-4. (PMID: 2559514)
JAMA. 2016 Dec 27;316(24):2588. (PMID: 28027353)
PLoS Negl Trop Dis. 2014 Feb 06;8(2):e2681. (PMID: 24516683)
Enferm Infecc Microbiol Clin (Engl Ed). 2018 Jan;36(1):21-23. (PMID: 28007310)
PLoS Negl Trop Dis. 2016 Apr 19;10(4):e0004682. (PMID: 27093158)
Emerg Infect Dis. 2015 Feb;21(2):359-61. (PMID: 25625872)
Cell Rep. 2016 Sep 20;16(12):3208-3218. (PMID: 27612415)
J Clin Virol. 2016 Apr;77:69-70. (PMID: 26921737)
Lancet Infect Dis. 2016 Oct;16(10):1106-1107. (PMID: 27676340)
PLoS Pathog. 2013 Jan;9(1):e1003118. (PMID: 23300459)

T32 OD011124 United States OD NIH HHS

Keywords: Histology; Immunohistochemistry; Mouse model; Neutralizing antibody; Pathogenesis; Zika virus

0 (Antibodies, Viral)

Date Created: 20170420 Date Completed: 20170424 Latest Revision: 20240325

20240325

PMC5395720

10.1186/s12985-017-0749-x

28420392